ERBB2 and triple-negative breast carcinoma: While the breast cancer subtypes positive for one or more of the receptors (ER, PR, or HER2) are treated by hormonal intervention, the triple-negative breast cancers (TNBC) will not benefit from the hormone-based therapy and treatment.